Assays by Agena OncoFOCUS™ Panel v3

This application note describes the development of the Assays by Agena OncoFOCUS Panel v3 for the retrospective testing of archived CRC samples. It has been known for several years that patients with metastatic colorectal adenocarcinoma who harbor an activating mutation in the Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2 will not benefit from monoclonal antibodies targeting the EGFR. Recent research evaluating anti-EGFR monoclonal antibodies has indicated that up to 20% of the KRAS exon 2 wild type tumors may contain other RAS mutations that are similarly predictive of drug resistance. Currently, common KRAS testing methodologies only assay codons 12/13 in exon 2 and sometimes codon 61 in exon 3.